Sarepta Therapeutics (SRPT) EBT Margin (2010 - 2026)

Sarepta Therapeutics' EBT Margin history runs 15 years deep, the most recent figure standing at 46.96% for Q1 2026.

• In Q1 2026, EBT Margin rose 33460.0% year-over-year to 46.96%; the TTM figure through Mar 2026 stood at 1.12% (up 1124.0% YoY), while the FY2025 annual figure was 37.67%, down 5138.0% from the prior year.
• EBT Margin for Q1 2026 stood at 46.96%, up from 62.83% in the prior quarter.
• The five-year high for EBT Margin was 46.96% in Q1 2026, with the low at 287.64% in Q1 2025.
• The 5-year median for EBT Margin is 5.58% (2023), against an average of 44.08%.
• The sharpest annual moves came in 2025 and 2026: EBT Margin slumped 29766 bps in 2025, then soared 33460 bps in 2026.
• Sarepta Therapeutics' EBT Margin stood at 38.93% in 2022, then plunged by 90 bps to 3.74% in 2023, then soared by 597 bps to 26.08% in 2024, then sank by 341 bps to 62.83% in 2025, then surged by 175 bps to 46.96% in 2026.
• Business Quant data shows SRPT's EBT Margin at 46.96% in Q1 2026, 62.83% in Q4 2025, and 48.59% in Q3 2025.